A patented ophthalmic formulation poised to transform cataract treatment for 94 million patients worldwide — where no FDA-approved pharmacological alternative exists today.
Cataracts remain the leading cause of blindness worldwide. An estimated 17 million people were bilaterally blind from cataracts in 2020, representing about 35% of all global cases of blindness.
So far, the only effective treatment for cataracts is surgery. However, accessibility and cost remain significant barriers. The FDA has not yet approved any non-surgical pharmacological drug to prevent, delay, or cure cataracts.
Despite the enormous global burden, cataract patients today face a stark reality.
Invasive surgery remains the sole effective treatment — a significant barrier for millions.
Cost and limited access to surgical facilities leave countless patients untreated globally.
The FDA has not yet approved any pharmacological drug to prevent, delay, or cure cataracts.
Opcure is an ophthalmic formulation — eye drops with therapeutically effective concentrations of a zinc compound and an antihistamine — patented in the US and China, with pending patents in Canada, Europe, and India.
Out of 230 volunteers, 90% demonstrated positive results in our observational study.
90% positive resultsThe active ingredients have a well-established safety profile backed by years of clinical use.
Clinically proven ingredientsSelf-administered eye drops, applied four times daily. No surgical intervention required.
Self-administeredA highly cost-effective alternative to cataract surgery for eligible patients worldwide.
Cost-effectiveThe cataract treatment market represents one of the largest opportunities in ophthalmology — and Opcure's patent portfolio covers the majority of it.
A compelling opportunity at the intersection of innovation, impact, and returns.
Two global leaders in ophthalmology have expressed interest through their external innovation units in the U.S. and Europe, contingent on receiving additional clinical study results.
The primary goal is to secure a licensing partnership with a multinational pharmaceutical company in exchange for royalty revenues.
ROI is expected in three stages: an upfront lump sum payment from the licensing agreement (anticipated 2027), followed by milestone-based payments, then ongoing royalties from product sales starting 2033–2034 after FDA approval.
By investing in Opcure, you invest in a company that owns the patent rights and its future revenue streams — at the earliest and most advantageous stage.
This investment opportunity offers the potential for remarkable financial returns by pioneering a new treatment class globally, while also making a significant positive impact on the lives of millions worldwide.
A clear, milestone-driven path from clinical validation to global licensing.
For inquiries, investment opportunities, or partnerships
team@opcure.net